UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

British journal of cancer, 2017-10, Vol.117 (9), p.1269-1277

2017

Volltextzugriff (PDF)

Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)

Targeted oncology, 2015-06, Vol.10 (2), p.277-286

2015

Volltextzugriff (PDF)

Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)

Annals of oncology, 2016-09, Vol.27, p.iv18

2016

Volltextzugriff (PDF)

Efficacy and safety of dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)

Annals of oncology, 2016-10, Vol.27, p.vi215-vi215

2016

Volltextzugriff (PDF)

Retrospective observational study of Vinflunine (VFL) in patients (pts) with transitional cell carcinoma of the urothelial tract (TCCU): final results of a real world population study (MOVIE-GOIRC01/2014 trial)

Annals of oncology, 2016-09, Vol.27, p.iv33

2016

Volltextzugriff (PDF)

Efficacy and Safety of Dose-Dense Chemotherapy with Modified TCF Regimen (TCF-DD) in Elderly Patients with Metastatic Gastric Cancer (MGC)

Annals of oncology, 2012-09, Vol.23, p.ix232

2012

Volltextzugriff (PDF)

693P - Efficacy and Safety of Dose-Dense Chemotherapy with Modified TCF Regimen (TCF-DD) in Elderly Patients with Metastatic Gastric Cancer (MGC)

Annals of oncology, 2012-09, Vol.23, p.ix232-ix232

2012

Volltextzugriff (PDF)

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

ESMO open, 2023-02, Vol.8 (1), p.100777-100777, Article 100777

2023

Volltextzugriff (PDF)

Long-term effects of a program of bladder preservation using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Analysis of biologic predictive factors and health-related quality of life (QOL)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e16014-e16014

2009

Volltextzugriff (PDF)

Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4142-4142

2010

Volltextzugriff (PDF)

Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4615-4615

2010

Volltextzugriff (PDF)

High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with oxaliplatin, folinic acid (FA), 5-fluorouracil (5-FU) and irinotecan (COFFI) in metastatic gastric cancer (MGC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4570-4570

2008

Volltextzugriff (PDF)

Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5121-5121

2008

Volltextzugriff (PDF)

Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15586-15586

2007

Volltextzugriff (PDF)

Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15068-15068

2007

Volltextzugriff (PDF)

Gefitinib (G) plus interleukin-2 (IL-2) in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.18042-18042

2007

Volltextzugriff (PDF)

Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14117-14117

2006

Volltextzugriff (PDF)

A Cultural Phenomenology of Qigong: Qi Experience and the Learning of a Somatic Mode of Attention

Anthropology of consciousness, 2023-03, Vol.34 (1), p.97-129

Lazzarelli, Alessandro

2023

Volltextzugriff (PDF)

Attenuation of negative effects of senescence in human skin using an extract from Sphingomonas hydrophobicum: development of new skin care solution

International journal of cosmetic science, 2019-08, Vol.41 (4), p.391-397

2019

Volltextzugriff (PDF)

EPISTOLA DI ENOCH

Bruniana & campanelliana, 2016-01, Vol.22 (2), p.577-594

2016

Volltextzugriff (PDF)

Reconsidering Religious Experience from the Perspective of Phenomenological Anthropology

Arc (Montréal, Québec), 2012-12, Vol.40

Lazzarelli, Alessandro

2012

Volltextzugriff (PDF)

High baseline lymphocyte count is a predictive biomarker of prolonged time to progression in patients with advanced solid tumors receiving checkpoint inhibitors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14532-e14532

2017

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(46)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)

Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

Efficacy and safety of dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)

Retrospective observational study of Vinflunine (VFL) in patients (pts) with transitional cell carcinoma of the urothelial tract (TCCU): final results of a real world population study (MOVIE-GOIRC01/2014 trial)

Effectiveness and possible molecular factors predictive of clinical outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: a multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

Efficacy and Safety of Dose-Dense Chemotherapy with Modified TCF Regimen (TCF-DD) in Elderly Patients with Metastatic Gastric Cancer (MGC)

693P - Efficacy and Safety of Dose-Dense Chemotherapy with Modified TCF Regimen (TCF-DD) in Elderly Patients with Metastatic Gastric Cancer (MGC)

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Long-term effects of a program of bladder preservation using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Analysis of biologic predictive factors and health-related quality of life (QOL)

Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study

Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG)

High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with oxaliplatin, folinic acid (FA), 5-fluorouracil (5-FU) and irinotecan (COFFI) in metastatic gastric cancer (MGC)

Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)

Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial

Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study

Gefitinib (G) plus interleukin-2 (IL-2) in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study

A Cultural Phenomenology of Qigong: Qi Experience and the Learning of a Somatic Mode of Attention

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

Attenuation of negative effects of senescence in human skin using an extract from Sphingomonas hydrophobicum: development of new skin care solution

EPISTOLA DI ENOCH

Reconsidering Religious Experience from the Perspective of Phenomenological Anthropology

High baseline lymphocyte count is a predictive biomarker of prolonged time to progression in patients with advanced solid tumors receiving checkpoint inhibitors

Aktive Filter

Suchergebnisse filtern